Institutional members access full text with Ovid®

Share this article on:

Commentary: Revised Susceptibility BreakpointsFear, Loathing and Good Science

Dudley, Michael N. PharmD*; Ambrose, Paul G. PharmD; Jones, Ronald N. MD

The Pediatric Infectious Disease Journal: September 2013 - Volume 32 - Issue 9 - p 970–971
doi: 10.1097/INF.0b013e3182a1b8cd
Commentary

From *Rempex Pharmaceuticals, San Diego, California; Institute for Clinical Pharmacodynamics, Latham, New York; and JMI Laboratories, North Liberty, Iowa.

Accepted for publication June 21, 2013.

The authors have no funding or conflicts of interest to disclose.

Address for correspondence: Michael N. Dudley, PharmD, Rempex Pharmaceuticals, San Diego, CA 92121. E-mail: mdudley@rempexpharma.com.

© 2013 by Lippincott Williams & Wilkins, Inc.